Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement
Advertisement
Opinion

Chanticleer

Today

Chemist Warehouse’s deal to list via Sigma Healthcare is part way through an ACCC merger review.

Why big Sigma backer sold down ahead of Chemist Warehouse ruling

It is usually worth following the money in merger deals, which makes trading in Sigma Healthcare interesting.

  • Anthony Macdonald

Yesterday

The float of APM made founder Megan Wynne a billionaire, but investors haven’t fared quite so well.

Why a blockbuster IPO would be better off in private equity hands

We all like to see businesses list on the ASX, but APM is one that would be better in private equity hands. Its credibility is shot.

  • Anthony Macdonald
Orora went big with an offshore M&A deal right as its core business was softening.

Packaging group hits the turps, investors stuck with the hangover

A once boring packaging company is doing what it can to make investors more wary of big offshore M&A.

  • Updated
  • Anthony Macdonald

This Month

Davind Livingstone.

Meet the Australian running Citi’s new team of 6000 bankers

From running Credit Suisse and Citi in Australia, to being involved in the biggest reshuffle at Citi in 25 years, David Livingstone says he wouldn’t have it any other way.

  • Updated
  • Anthony Macdonald
Australian PE firms have slowed fundraising and dealmaking activity.

Private capital’s surprisingly sluggish year prompts rethink

Just when we thought the push to private capital was flying, new fundraisings have slowed down. Is it a hiccup, or more?

  • Anthony Macdonald
Advertisement

March

Global trade patterns have changed radically in the past 50 years.

Lessons from a fund that has beaten the market for 50 years

Since 1973, Capital Group’s New Perspective Fund has ridden the shifting tides of world trade. With deglobalisation taking hold, will the strategy hold up?

  • James Thomson
Cochlear chief executive Dig Howitt has had a great story to tell investors at recent results.

Can a vaccine slow down the Cochlear train?

Cochlear is firing for investors, but you have to wonder whether everyone’s getting a bit carried away.

  • Anthony Macdonald
Robert Millner, Washington H Soul Pattinson & Co chairman, is a rare business leaded not afraid to ruffle feathers.

Soul Patts’ Millner rails against secretive new laws

Two words are frightening senior Australian executives; few are willing to say them publicly. The words are “nature positive”.

  • Anthony Macdonald
Banking technology is a fraught subject for investors.

Westpac’s $3.5b tech catch-up is a warning to ANZ

Fifteen years after buying St George, Westpac is finally unifying its banking systems. ANZ investors will hope they’re not hearing about the Suncorp integration in 2039. 

  • James Thomson
The bulls have started 2024 firmly in charge. But the bears aren’t done with yet.

Ninety days to remember and what could go wrong from here

Despite a plethora of risks, the first quarter of 2024 has turned out to be better than expected across markets, economics and geopolitics. But don’t get comfortable.

  • Updated
  • James Thomson
BlackRock CEO Larry Fink.

The shocking data that stopped Larry Fink cold

“I’ve seen a lot of numbers. But no single data point has ever concerned me more than this one,” the CEO of BlackRock says.

  • James Thomson
Commonwealth Bank chief executive Matt Comyn is cautious about the year ahead.

The feeding frenzy that sent CBA shares to $120

Commonwealth Bank’s staggering $120 a share price came up a few times at The Australian Financial Review Banking Summit. Brian Johnson nailed why it had run so hard.

  • Anthony Macdonald
Ross McEwan, Matt Comyn, Peter King and Antonia Watson at the AFR Banking Summit.

It’s time for banks to take more risk, not less

While the prudential regulator sees more stresses ahead for banks, top CEOs worry the sector has become too risk-averse. They’ve got three big ideas to drive growth. 

  • James Thomson
Seven Group CEO Ryan Stokes is also chairman of Boral.

Seven starts throwing haymakers to get Boral bid moving

An independent expert’s report is the tip of the iceberg in the battle for Boral. The fight is ramping up.

  • Updated
  • Anthony Macdonald
Solomon Lew is set to radically reshape his empire.

Solomon Lew’s $3b bet on global growth

Premier Investments is set to split itself in three, launching the Smiggle and Peter Alexander divisions onto the ASX as separate companies. 

  • Updated
  • James Thomson
Advertisement
NAB boss Ross McEwan says the scars of the royal commission cannot be forgotten.

Ross McEwan reveals his biggest win from 40 years in banking

In an extraordinary four decades in banking, Ross McEwan has rescued two big banks from crises. And all while driving a Holden ute.

  • James Thomson
HMC Capital’s David Di Pilla is a key player in the Healthscope situation.

David Di Pilla draws line in the sand at Healthscope

David Di Pilla’s HMC Capital wants to make a few things clear about where it stands as a landlord to struggling hospital operator Healthscope. 

  • James Thomson
John McGrath, founder and chief executive of McGrath, is wrapping up time on the ASX.

Why real estate agent John McGrath couldn’t crack the ASX

His brokerage broke the golden rule of IPOs – and paid for it ever since. It’s a reminder that for every success, dozens never quite crack the big time.

  • Anthony Macdonald
MMA Prestige, one of ASX-listed MMA Offshore’s biggest earners, is now working on offshore windfarms.

Surprise energy transition story in Monday’s $1b buyout

The last time vessel owner MMA Offshore hit the headlines, it was an offshore oil and gas services group going broke. Now it has a $1 billion bid, and investors can thank the energy transition.

  • Anthony Macdonald
Macquarie says investors should be cautious about markets overheating.

Macquarie’s new FOMO meter flashes red, points to these eight stocks

Macquarie’s new measure of investor sentiment should be a warning sign for those chasing this impressive rally.

  • James Thomson